Agnes Bonifacius

Weitere Beteiligungen

• 21.09.2023

  08:54 – 09:06 10 Min. 2 Min.

  • Freier Vortrag
  • VS-10-3

  Vitamin C conditioning creates CAR-T cells with superior cytotoxic capacity and metabolic fitness to combat the immunosuppressive tumor micromilieu

   Immunotherapy
• 21.09.2023

  09:30 – 09:38 7 Min. 1 Min.

  • Freier Vortrag
  • VS-10-7

  Overcoming immune escape in EBV-associated PTLD by understanding the two levels of immunosuppression: the tumor microenvironment and iatrogenic immunosuppression

   Immunotherapy
• 21.09.2023

  09:38 – 09:48 8 Min. 2 Min.

  • Freier Vortrag
  • VS-10-8

  Discovery of the human cytomegalovirus-specific peptide repertoire naturally processed and presented by infected human antigen presenting cells

   Immunotherapy
• 22.09.2023

  13:30 – 13:40 8 Min. 2 Min.

  • Freier Vortrag (Reinhold-Eckstein-Investigator-Award)
  • VS-22-1

  Engineered T cells selectively depleting alloreactive B cells and resisting immunosuppressive treatment as tool to combat AMR following solid organ transplantation

   Immunotherapy
• 22.09.2023

  14:00 – 14:10 8 Min. 2 Min.

  • Freier Vortrag
  • VS-22-4

  Next generation LMP2A-targeting TCR-recombinant T-Cells with inducible expression of Il-18 as promising tool to treat various EBV-associated malignancies

   Immunotherapy
• 22.09.2023

  14:10 – 14:20 8 Min. 2 Min.

  • Freier Vortrag
  • VS-22-5

  4^th generation CAR-T cells with inducible cytokine expression targeting CD176 to overcome the immunosuppressive tumor milieu in lung cancer

   Immunotherapy